Compared to 2 months back Lero has got enough publicity - in reality in scientific community related to CV19 it is well known as those scientist read stuff and keep track of progress around them.
At this time that really does not matter. RDHL got their P2 trial approved for 40 patients, CYDY 75.
Despite really good results in so many eIND patients, FDA has not granted CUA.
This drug is not mentioned by Dr F, CNN panels and nor Dr Gupta.
So till the time it reaches that level all these efforts will not help the co or share price.
Other key is lack of finances. NP has miserably failed in getting finances like NVAX. He has not been able to convince any BP to do partnership, nor Bill-Melinda Gates foundation, NIH, people like baker bros.
That and staying on OTC makes CYDY look like a shady company and not many give much weight to it
News 
Market Data 
Discover 
AI
